Next-Generation Bispecific Nanobody Approach for Neuroblastoma: Dual Targeting of ALK and CD3 Complex
VHH-P460 is an innovative humanized nanobody-based bispecific T cell engager designed to target the ALK receptor tyrosine kinase (ALK) and the CD3 Complex (T Cell Receptor Complex). Currently in the Biological Testing development stage, VHH-P460 demonstrates high potential in the treatment of neuroblastoma, a childhood malignancy with significant unmet clinical needs. Leveraging the specificity of ALK and the immune-activation capacity of CD3 Complex engagement, this program aims to create a targeted, immune-enhancing therapeutic strategy poised for advancement within the neuroblastoma treatment landscape.
| Candidate | VHH-P460 |
| Target | ALK receptor tyrosine kinase (ALK) CD3 Complex (T Cell Receptor Complex) |
| Modality | humanized bispecific VHH |
| Indication | Neuroblastoma |
Licensing Opportunity
VHH-P460 is currently open for external licensing and partnership opportunities. Biopharmaceutical companies and collaborators interested in advancing this novel bispecific nanobody program for neuroblastoma are encouraged to initiate discussions for co-development or out-licensing arrangements.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P460 |
Modality
VHH-P460 utilizes a modular design featuring a single-domain antibody (nanobody) directed against the glycine-rich region of human ALK, fused to a single-chain variable fragment (scFv) derived from an anti-CD3 antibody. This construct is further linked to a human IgG1 Fc domain, forming a bispecific T cell engager. The nanobody’s small molecular size enables enhanced tissue penetration and stability, both critical attributes for effective tumor targeting in neuroblastoma. The bispecific format allows simultaneous recruitment of T cells and precise localization to tumor cells, offering the prospect of improved antitumor efficacy and reduced off-target toxicity relative to conventional antibody therapies.
Target
The primary targets for VHH-P460 are ALK and the CD3 Complex. ALK is a receptor tyrosine kinase involved in cellular growth signaling and is aberrantly expressed in various childhood cancers, notably neuroblastoma. The CD3 Complex is a critical component of the T cell receptor involved in T cell activation. ALK is predominantly found in neural tissue and is overexpressed or mutated in neuroblastoma cells, providing a strategic target for selective tumor cell recognition. CD3 Complex is specifically expressed on T cells, enabling immune redirection. VHH-P460's bispecific engagement of ALK and CD3 Complex harnesses the innate specificity of each target, enabling direct T cell-mediated cytotoxicity against ALK-expressing tumor cells. This dual-targeting approach positions ALK and CD3 Complex as highly attractive and validated targets for transformative immunotherapeutic strategies in pediatric oncology.
Mechanism of Action
VHH-P460 functions as a bispecific T cell engager by simultaneously binding ALK on neuroblastoma cells and the CD3 Complex on cytotoxic T cells. This dual binding brings effector T cells into close proximity with malignant cells, facilitating targeted activation and immune-mediated tumor cell lysis. The nanobody platform enables flexible engineering, offering opportunities for future therapeutic adaptations such as antibody-drug conjugates (ADCs) or other bispecific constructs. By modulating signal transduction pathways and redirecting T cell activity toward tumor cells, VHH-P460 promises a highly selective antitumor immune response with minimized collateral damage to healthy tissues.
Neuroblastoma
Neuroblastoma is one of the most common solid tumors in children, primarily originating from neural crest cells of the sympathetic nervous system. Its incidence is notable in pediatric oncology, carrying a significant burden due to its aggressive nature and occurrence at a young age. Current treatments include multimodal approaches such as chemotherapy, surgical resection, radiotherapy, immunotherapy, and, in select cases, targeted therapies. Despite these interventions, high-risk neuroblastoma is associated with poor long-term survival, relapse, and notable treatment-related morbidity. The limited efficacy and toxicity of available therapies underscore the urgent need for more targeted, effective, and safer treatment modalities. By engaging both ALK—a frequently upregulated driver in neuroblastoma—and T cell immunity through CD3 Complex, VHH-P460 offers the promise of precise and potent immunotherapy, aiming to address critical gaps in current neuroblastoma treatment paradigms.